ACR recommends TNF biologic and "treat to target" approach for all individuals with Psoriatic Arthritis.
Nutrition recommendations for managing chronic inflammatory conditions. Answers to FAQ's from Dr Manno of Johns Hopkins.
Cosentyx Highly Effective for Treatment of Scalp Psoriasis
New research shows psoriasis increases risk of bone fractures.
FDA Extends Simponi Approval to Psoriatic Arthritis and Ankylosing Spondylitis
Better Outcomes with Intensive Treatment in Psoriatic Arthritis
Drug Payment Assistance Programs for Rheumatoid & Psoriatic Arthritis
National Psoriasis Foundation has released dietary recommendations for psoriasis and psoriatic arthritis.
A leading doctor outlines the role of exercise in managing AS, RA, PsA, SLE and other inflammatory conditions.
Doctors from the UK report on the increased risk of infection with Remicade in the British Journal of Dermatology
Oral Methotrexate Effective for Juvenile Arthritis
Discussion of how psoriatic disease affects women physically and emotionally in all aspects of work and life.
Cancer patients treated with checkpoint inhibitors need to bring symptoms of joint pain to their doctors attention.
Spine Community News:
IL-23 inhibitor Tremfya effective for treatment of psoriatic arthritis
Research suggests that individuals with psoriasis are at increased cancer risk and this may be associated with treatment
theRAConnection Survey Results Suggest Majority of Patients Don’t Discuss Treat to Target Goals With Their Physician
What natural or alternatives treatments have others used that have helped?
Stress may play a role in inflammation that causes pain - learn about Tai Chi, Relaxation, and other coping techniques.
The JAK inhibitor Rinvoq represents a new treatment option for Psoriatic Arthritis
New study suggests Enbrel alone more effective than MTX or combination.
FDA approves third IL-23 inhibitor for treatment of plaque psoriasis.
Simponi®(golimumab)is one of five marketed TNF inhibitors(TNFi) that is FDA approved for use in psoriatic arthritis(PsA)
Doctors evaluated mobility, self-care, and activities of daily living in Cosentyx treated patients.
Dual Inhibition of IL-17 appears promising for treatment of PsA according to University of Rochester led clinical trial
Research suggests filgotinib can benefit psoriatic arthritis patients with difficult to control disease.
Researchers provide updates on Cosentyx, Tremfya, Otezla, Filgotinib, and Taltz treatment for Psoriatic Arthritis
Understand the administration, side effects and answers to frequently asked questions about Taltz® (Ixekizumab).